Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 19594734)


Costs of cancer care for use in economic evaluation: a UK analysis of patient-level routine health system data.

Hall PS, Hamilton P, Hulme CT, Meads DM, Jones H, Newsham A, Marti J, Smith AF, Mason H, Velikova G, Ashley L, Wright P.

Br J Cancer. 2015 Mar 3;112(5):948-56. doi: 10.1038/bjc.2014.644. Epub 2015 Jan 20.


Prostate cancer screening: going beyond the clinical evidence.

Krahn M.

CMAJ. 2014 Nov 4;186(16):1201-2. doi: 10.1503/cmaj.141252. Epub 2014 Oct 27. No abstract available.


Active surveillance for low-risk prostate cancer compared with immediate treatment: a Canadian cost comparison.

Dragomir A, Cury FL, Aprikian AG.

CMAJ Open. 2014 Apr 24;2(2):E60-8. doi: 10.9778/cmajo.20130037. eCollection 2014 Apr.


Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study.

de Oliveira C, Bremner KE, Pataky R, Gunraj N, Chan K, Peacock S, Krahn MD.

CMAJ Open. 2013 Jan 16;1(1):E1-8. doi: 10.9778/cmajo.20120013. eCollection 2013 Jan.


Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.

Krahn MD, Bremner KE, Luo J, Alibhai SM.

Curr Oncol. 2014 Jun;21(3):e457-65. doi: 10.3747/co.21.1865.


Drug costs in the management of metastatic castration-resistant prostate cancer in Canada.

Dragomir A, Dinea D, Vanhuyse M, Cury FL, Aprikian AG.

BMC Health Serv Res. 2014 Jun 13;14:252. doi: 10.1186/1472-6963-14-252.


Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.

Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S.

Int J Cancer. 2014 Aug 15;135(4):939-47. doi: 10.1002/ijc.28732. Epub 2014 Feb 4.


Direct cost for initial management of prostate cancer: a systematic review.

Sanyal C, Aprikian AG, Chevalier S, Cury FL, Dragomir A.

Curr Oncol. 2013 Dec;20(6):e522-31. doi: 10.3747/co.20.1630.


Analysis of urological procedures in men who died from prostate cancer using a population-based approach.

Babaian K, Truong M, Cetnar J, Cross DS, Shi F, Ritter MA, Jarrard DF.

BJU Int. 2013 Mar;111(3 Pt B):E65-70. doi: 10.1111/j.1464-410X.2012.11517.x. Epub 2012 Nov 6.


Direct cost associated with acquired brain injury in Ontario.

Chen A, Bushmeneva K, Zagorski B, Colantonio A, Parsons D, Wodchis WP.

BMC Neurol. 2012 Aug 17;12:76. doi: 10.1186/1471-2377-12-76.


Techniques for estimating health care costs with censored data: an overview for the health services researcher.

Wijeysundera HC, Wang X, Tomlinson G, Ko DT, Krahn MD.

Clinicoecon Outcomes Res. 2012;4:145-55. doi: 10.2147/CEOR.S31552. Epub 2012 Jun 1.


Active surveillance for prostate cancer compared with immediate treatment: an economic analysis.

Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP.

Cancer. 2012 Jul 15;118(14):3512-8. doi: 10.1002/cncr.26688. Epub 2011 Dec 16.


Differences in treatment patterns among patients with castration-resistant prostate cancer treated by oncologists versus urologists in a US managed care population.

Engel-Nitz NM, Alemayehu B, Parry D, Nathan F.

Cancer Manag Res. 2011;3:233-45. doi: 10.2147/CMR.S21033. Epub 2011 Jul 4.


End-of-life care for lung cancer patients in the United States and Ontario.

Warren JL, Barbera L, Bremner KE, Yabroff KR, Hoch JS, Barrett MJ, Luo J, Krahn MD.

J Natl Cancer Inst. 2011 Jun 8;103(11):853-62. doi: 10.1093/jnci/djr145. Epub 2011 May 18.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk